ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.50
−2.97%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.52
From 52W high−80.28%
Volume234276.00
Market cap$9.78M
P/E (TTM)—
P/S (TTM)8.4x
Div yield—
Key dataOct 19, 2026
Open
$0.52
From 52W high
−80.28%
Volume
234276.00
Market cap
$9.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
56.4
MomentumView details →
1D Return
−2.97%
YTD Return
−44.42%
SummaryUpdated Jun 1, 2026
Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a clinical-stage pharmaceutical company founded in 2018 and based in La Jolla, California. The company specializes in developing abuse-resistant and overdose-protection opioid medications to address the ongoing opioid crisis in the United States. Since going public in March 2018, Ensysce has focused on advancing its proprietary drug delivery platforms through clinical trials while generating revenue from licensing agreements and research collaborations.
Similar companies
Latest newsMore news →
Ensysce Biosciences submitted the Phase 2a protocol CYBIO_001 for its drug candidate CY200 to the UK Medicines and Healthcare products Regulatory Agency for a study in Complex Regional Pain Syndrome Type 1.25d agoEnsysce Biosciences hosted a symposium on its CRPS program at PainWeek 2026, attended by more than 320 pain management professionals.34d agoRichard Langford, Chief Medical Officer of Cy Biopharma, was selected to present at the U.S. Food and Drug Administration's public hearing on the potential future therapeutic use of psychedelic drugs, held on September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.35d ago